Anna Planaguma
Overview
Explore the profile of Anna Planaguma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orellana A, Garcia-Gonzalez V, Lopez R, Pascual-Guiral S, Lozoya E, Diaz J, et al.
PLoS One
. 2018 Jan;
13(1):e0189247.
PMID: 29320511
Thymic stromal lymphopoietin (TSLP) is a cytokine released by human lung epithelium in response to external insult. Considered as a master switch in T helper 2 lymphocyte (Th2) mediated responses,...
2.
Li C, Lee P, Sun Y, Gu X, Zhang E, Guo Y, et al.
J Exp Med
. 2014 Jan;
211(1):15-28.
PMID: 24395886
Lymphangioleiomyomatosis (LAM) is a progressive neoplastic disorder that leads to lung destruction and respiratory failure primarily in women. LAM is typically caused by tuberous sclerosis complex 2 (TSC2) mutations resulting...
3.
Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, et al.
J Allergy Clin Immunol
. 2013 Apr;
132(3):547-553.
PMID: 23608729
Background: The relationship between anti-inflammatory lipoxins and proinflammatory leukotrienes might be important in the pathobiology and severity of asthma. Objective: We sought to investigate whether exhaled breath condensate (EBC) lipoxin...
4.
Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling
Planaguma A, Levy B
Future Lipidol
. 2011 Sep;
3(6):697-704.
PMID: 19293940
Counter-regulatory lipid mediators are generated during airway inflammation to promote resolution. Defects in the production of these lipid mediators have now been associated with several diseases of persistent airway inflammation....
5.
Ferre N, Martinez-Clemente M, Lopez-Parra M, Gonzalez-Periz A, Horrillo R, Planaguma A, et al.
Am J Physiol Gastrointest Liver Physiol
. 2009 Jan;
296(3):G553-62.
PMID: 19136384
The contribution of metabolic factors to the severity of liver disease is not completely understood. In this study, apolipoprotein E-deficient (ApoE-/-) mice were evaluated to define potential effects of hypercholesterolemia...
6.
Lopez-Parra M, Titos E, Horrillo R, Ferre N, Gonzalez-Periz A, Martinez-Clemente M, et al.
J Lipid Res
. 2008 Jul;
49(12):2513-23.
PMID: 18645210
As 5-lipoxygenase (5-LO) is an emerging target in obesity and insulin resistance, we have investigated whether this arachidonate pathway is also implicated in the progression of obesity-related fatty liver disease....
7.
Planaguma A, Kazani S, Marigowda G, Haworth O, Mariani T, Israel E, et al.
Am J Respir Crit Care Med
. 2008 Jun;
178(6):574-82.
PMID: 18583575
Rationale: Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A(4) (LXA(4)) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation....
8.
Horrillo R, Planaguma A, Gonzalez-Periz A, Ferre N, Titos E, Miquel R, et al.
J Pharmacol Exp Ther
. 2007 Sep;
323(3):778-86.
PMID: 17766677
In this study, we examined the relative contribution of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO), two major proinflammatory pathways up-regulated in liver disease, to the progression of hepatic inflammation and fibrosis....
9.
Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, Titos E, et al.
FASEB J
. 2006 Oct;
20(14):2537-9.
PMID: 17056761
Docosahexaenoic acid (DHA) is a omega-3 essential fatty acid that reduces the incidence and severity of a number of diseases. Recently, a novel series of DHA-derived lipid mediators with potent...
10.
Lopez-Parra M, Telleria N, Titos E, Planaguma A, Gonzalez-Periz A, Arroyo V, et al.
J Hepatol
. 2006 Apr;
45(2):221-9.
PMID: 16644059
Background/aims: Renal dysfunction is a frequent complication in advanced cirrhosis. The mechanisms underlying this complication have classically been addressed through conventional methods of study of candidate genes, but never on...